Successful concurrent chemoradiotherapy with cisplatin plus etoposide after incomplete resection for advanced thymic carcinoma

Ling Han; Baozhu Zhang; Shihai Wu

doi:10.1093/omcr/omz070

Successful concurrent chemoradiotherapy with cisplatin plus etoposide after incomplete resection for advanced thymic carcinoma

Oxf Med Case Reports. 2019 Aug 1;2019(8):omz070. doi: 10.1093/omcr/omz070.

Authors

Ling Han¹, Baozhu Zhang², Shihai Wu³

Affiliations

¹ Department of Otorhinolaryngology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, China.
² Department of Oncology, The People's Hospital of Baoan Shenzhen, The Affiliated Baoan Hospital of Southern Medical University, Shenzhen, China.
³ Department of Radiation Oncology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, China.

Abstract

The optimal therapy for advanced thymic carcinoma has long been controversial. Despite that complete (R0) resection is recommend as the first-line treatment, multidisciplinary approach including chemotherapy and radiotherapy should be considered for patients who lost the operation chance or received incomplete resection. Here, we present a case who received concurrent chemoradiotherapy (CCRT) after cytoreductive surgery. A complete response was observed and the patient has remained disease free for over 4 years. To our knowledge, this is the first report to demonstrate the efficacy of CCRT with cisplatin plus etoposide after incomplete surgery for advanced thymic carcinoma.